Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

• Published in: Leukemia Research and Treatment 2015-01, Vol.2015, p.49-60
• Main Authors: Rochau, Ursula, Kluibenschaedl, Martina, Stenehjem, David, Kuan-Ling, Kuo, Radich, Jerald, Oderda, Gary, Brixner, Diana, Siebert, Uwe
• Format: Article
• Language: English
• Subjects: Cancer; Cancer therapies; Care and treatment; Chemotherapy; Chronic illnesses; Chronic myeloid leukemia; Colleges & universities; Costs; Decision making; Economic aspects; Health sciences; Hospitals; Leukemia; Medical prognosis; Medical research; Mortality; Pharmaceutical industry; Public health
• ISSN: 2090-3219; 2090-3227
• DOI: 10.1155/2015/982395

Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for CML patients within the US health care context. We evaluated 18 treatment strategies regarding survival, quality-adjusted survival, and costs. For model parameters, the literature data, expert surveys, registry data, and economic databases were used. Evaluated strategies included imatinib, dasatinib, nilotinib, bosutinib, ponatinib, stem-cell transplantation (SCT), and chemotherapy. We developed a Markov state-transition model, which was analyzed as a cohort simulation over a lifelong time horizon with a third-party payer perspective and discount rate of 3%. Remaining life expectancies ranged from 5.4 years (3.9 quality-adjusted life years (QALYs)) for chemotherapy treatment without TKI to 14.4 years (11.1 QALYs) for nilotinib → dasatinib → chemotherapy/SCT. In the economic evaluation, imatinib → chemotherapy/SCT resulted in an incremental cost-utility ratio (ICUR) of $171,700/QALY compared to chemotherapy without TKI. Imatinib → nilotinib → chemotherapy/SCT yielded an ICUR of $253,500/QALY compared to imatinib → chemotherapy/SCT. Nilotinib → dasatinib → chemotherapy/SCT yielded an ICUR of $445,100/QALY compared to imatinib → nilotinib → chemotherapy/SCT. All remaining strategies were excluded due to dominance of the clinically superior strategies. Based on our analysis and current treatment guidelines, imatinib → nilotinib → chemotherapy/SCT and nilotinib → dasatinib → chemotherapy/SCT can be considered cost-effective for patients with CML, depending on willingness-to-pay.